Skip to main content

Table 2 Ongoing trials of inotuzumab ozogamicin (INO)

From: Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Reference

Phase

Disease

Intervention

Recruitment

NCT03441061

2

B-ALL with positive MRD

INO

Recruiting

NCT03677596

4

R/R B-ALL

Investigating lower dose level (1.2 mg/m2/cycle) for those with higher risk for liver toxicity or VOD.

Not yet recruiting

NCT03460522

2

Precursor B-cell ALL in 56–74 years old

INO induction followed by conventional chemotherapy

Recruiting

NCT02311998

1/ 2

Ph + B-ALL and CML-blast phase

Bosutinib plus INO

Recruiting

NCT01925131

1

Acute leukemia of ambiguous lineage, Recurrent Ph + B-ALL, Recurrent Burkitt Lymphoma

INO plus CVP (cyclophosphamide, Vincristine, Prednisone)

Recruiting

NCT03739814

2

Ph negative B-ALL

INO followed by Blinatumomab

Recruiting

NCT03851081

1/ 2

r/r B-ALL

INO plus Vincristine (liposomal)

Not yet Recruiting

NCT01664910

1/ 2

Conditioning regimen for HSCT

INO + plus Rituximab, Bendamustine and Fludarabine

Recruiting

NCT03249870

2

Ph negative B-ALL in 55 years or older

INO plus CVP induction

Recruiting

NCT03610438

2

ALL with positive MRD prior to HSCT

INO

Not yet recruiting

NCT03856216

2

Allogeneic SCT

Pre and Post HSCT INO

Not yet recruiting

NCT01371630

1/ 2

Untreated ALL in 60 years and older

INO plus combination chemotherapy

Not yet recruiting

NCT03150693

3

Newly diagnosed B-ALL in 18–39 years old

INO plus chemotherapy

Recruiting

NCT03094611

2

R/R ALL

Lower dose INO

Recruiting

NCT03488225

2

ALL

INO plus HyperCVAD

Recruiting

NCT01679119

2

DLBCL

INO plus R-CVP versus

Gem-R-CVP

Recruiting

NCT02981628

2

B-ALL in 1–21 years old

INO

Recruiting

NCT03628053

3

ALL

Tisagenlecleucel versus Blinatumomab or Inotuzumab

Not yet recruiting

  1. Abbreviations: R/R refractory /relapsed, CVAD cyclophosphamide vincristine Adriamycin dexamethasone, NHL non-Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma, ALL acute lymphoblastic leukemia, Gem gemcitabine, R rituximab, CVP cyclophosphamide vincristine prednisone, VOD veno-occlusive disease